Development of new methodologies for the chromogenic estimation of betrixaban concentrations in plasma

Medicine and Dentistry

• Plasma 100%
• Betrixaban 100%
• Assay 50%
• Heparin 50%
• Blood Clotting Factor 10a Inhibitor 50%
• Combination Therapy 33%
• Low Molecular Weight Heparin 33%
• Buffer 33%
• Fondaparinux 33%
• Donor 16%
• Adaptation 16%
• Inpatient 16%

Neuroscience

• Blood Clotting Factor 10a 100%
• Heparin 100%
• Low Molecular Weight Heparin 66%
• Fondaparinux 66%
• Interference 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Betrixaban 100%
• Heparin 50%
• Blood Clotting Factor 10a Inhibitor 50%
• Buffer 33%
• Low Molecular Weight Heparin 33%
• Fondaparinux 33%